Standout Papers

Adalimumab therapy for moderate to severe psoriasis: A ... 1994 2026 2004 2015 675
  1. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial (2007)
    Alan Menter, Stephen K. Tyring et al. Journal of the American Academy of Dermatology
  2. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis (2010)
    C.E.M. Griffiths, Bruce Strober et al. New England Journal of Medicine
  3. The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest (1994)
    Joshua L. Dunaief, Bruce Strober et al. Cell
  4. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials (2018)
    Kenneth B. Gordon, Bruce Strober et al. The Lancet
  5. Hidradenitis suppurativa (2019)
    Samantha R. Goldburg, Bruce Strober et al. Journal of the American Academy of Dermatology
  6. Bimekizumab versus Secukinumab in Plaque Psoriasis (2021)
    Kristian Reich, Richard B. Warren et al. New England Journal of Medicine
  7. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial (2022)
    April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology
  8. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial (2022)
    Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology

Immediate Impact

9 by Nobel laureates 18 from Science/Nature 86 standout
Sub-graph 1 of 16

Citing Papers

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
Psoriasis
2021 Standout
69 intermediate papers

Works of Bruce Strober being referenced

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
2018 Standout
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
2007 Standout
and 31 more

Author Peers

Author Last Decade Papers Cites
Bruce Strober 7289 4868 1561 1897 276 10.6k
Wolf‐­Henning Boehncke 8415 4271 1271 2658 355 12.9k
Diamant Thaçi 7915 7355 1615 3116 364 12.9k
Paolo Gisondi 5440 3162 914 2363 270 8.1k
Craig L. Leonardi 11088 6216 1980 2559 130 13.7k
Neil J. Korman 5384 3856 3046 2424 158 9.5k
Kenneth B. Gordon 13281 7428 2423 3138 198 16.0k
Robert Bissonnette 4469 6798 902 2135 300 10.9k
Jashin J. Wu 4662 2761 773 1576 358 7.2k
Gerald G. Krueger 7427 3515 1069 3062 119 9.6k
Knud Kragballe 5073 3533 1363 852 254 9.0k

All Works

Loading papers...

Rankless by CCL
2026